Results of a Phase I Trial of Induction Cisplatin, Docetaxel, 5-FU and Erlotinib followed by Cisplatin, Bevacizumab and Erlotinib with Radiotherapy for Advanced Head and Neck Cancer

被引：0
|
作者：
Ahn, P. [1 ]
Machtay, M. [2 ]
Anne, P. R. [1 ]
Wuthrick, E. [1 ]
Keane, W. M. [1 ]
Keane, W. M. [1 ]
Cognetti, D. [1 ]
Dicker, A. P. [1 ]
Axelrod, R. S. [1 ]
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[2] Case Western Reserve Univ Hosp, Cleveland, OH 44106 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2010年 / 78卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2010.07.1027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S437 / S437
页数：1
相关论文
共 50 条
  • [21] MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with Docetaxel, Cisplatin and 5-FU (DCF) in induction for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    Even, C.
    Texier, M.
    Le Tourneau, C.
    Marabelle, A.
    Chaput, N.
    Adam, J.
    Paci, A.
    Broutin, S.
    Ferte, C.
    Breuskin, I.
    Cupissol, D.
    Fayette, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck carcinomas
    Allal, AS
    Zwahlen, D
    Becker, M
    Dulguerov, P
    Mach, N
    STRAHLENTHERAPIE UND ONKOLOGIE, 2005, 181 : 134 - 134
  • [23] Induction chemotherapy with Docetaxel, Cisplatin and Cetuximab results in improved response rates if compared to Docetaxel, Cisplatin and 5-FU for locally advanced or inoperable squamous cell carcinoma of the head and neck: promising results of the Austrian multicentric phase II trial (AGMT)
    Keil, F.
    Hartl, M.
    Altorjai, G.
    Pecherstorfer, M.
    Berghold, A.
    Riedl, R.
    De Vries, A.
    Mayrbaeurl, B.
    Fridrik, M. A.
    Fuereder, T.
    Burian, M.
    Greil, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 56 - 57
  • [24] Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer
    Nogueira-Rodrigues, Angelica
    do Carmo, Claudio C.
    Viegas, Celia
    Erlich, Felipe
    Camisao, Claudia
    Fontao, Karina
    Lima, Roberta
    Herchenhorn, Daniel
    Martins, Renato G.
    Moralez, Giulliana M.
    Small, Isabele A.
    Ferreira, Carlos G.
    CLINICAL CANCER RESEARCH, 2008, 14 (19) : 6324 - 6329
  • [25] Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)
    Sanambar Sadighi
    Mohammad Ali Mohagheghi
    Ali Montazeri
    Zahra Sadighi
    BMC Cancer, 6
  • [26] Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)
    Sadighi, Sanambar
    Mohagheghi, Mohammad Ali
    Montazeri, Ali
    Sadighi, Zahra
    BMC CANCER, 2006, 6 (1)
  • [27] A Phase II study of docetaxel, cisplatin, and 5 FU induction chemotherapy followed by chemoradiotherapy in advanced nasopharyngeal cancer
    Bae, W.
    Cho, S.
    Hwang, J.
    Shim, H.
    Lee, J.
    Lim, S.
    Chung, W.
    Chung, I.
    EJC SUPPLEMENTS, 2009, 7 (02): : 488 - 489
  • [28] Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer
    Nogueira-Rodrigues, Angelica
    Moralez, Giulliana
    Grazziotin, Rachele
    Carmo, Claudio C.
    Small, Isabele A.
    Alves, Flavia V. G.
    Mamede, Marcelo
    Erlich, Felipe
    Viegas, Celia
    Triginelli, Sergio A.
    Ferreira, Carlos G.
    CANCER, 2014, 120 (08) : 1187 - 1193
  • [29] Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer
    Budach, V.
    Becker, E. -T.
    Boehmer, D.
    Badakhshi, H.
    Jahn, U.
    Wernecke, K. -D.
    Stromberger, C.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 (03) : 250 - 255
  • [30] Phase I trial of cisplatin, infusional 5-FU and irinotecan in advanced gastric cancer.
    Seguru, A
    Fernández-Martos, C
    Aparicio, J
    Campos, JM
    Vicent, J
    Busquier, I
    Molins, C
    Guillem, V
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 156S - 156S
12345